In a regulatory filing, TransMedics director James Tobin disclosed the sale of 10,000 common shares of the company on November 28 at a price of $70.14 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TMDX:
- TransMedics price target lowered to $80 from $99 at Canaccord
- TransMedics price target lowered to $100 from $110 at TD Cowen
- TransMedics Reports Third Quarter 2023 Financial Results
- TransMedics raises FY23 revenue view to $222M-$230M from $180M-$190M
- TransMedics reports Q3 EPS (78c), consensus (16c)